CEST- Glucose Enhanced MRI for Metastatic Brain Tumours
Status:
Terminated
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This project will compare two MRI contrast agents in metastatic brain tumours in humans. More
specifically, the investigators will compare the tumour contrast obtained using glucose
versus the current standard gadolinium-based contrast agent (GBCA, gadobutrol, trade name
Gadovist, will be used).
First, participants will receive a glucose bolus injection followed by glucose enhanced MRI.
Second, participants will receive a Gd-DTPA bolus injection followed by Gd-DTPA enhanced MRI.
Both contrast studies will be performed during the same MRI study, which will be under one
hour long.